THE PROMISE OF SCIENCE, REALIZED™
THE PROMISE OF SCIENCE, REALIZED™
THE PROMISE OF SCIENCE, REALIZED™
Our Science

We are Sarepta Therapeutics: a biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. Our primary focus is on rapidly advancing Duchenne muscular dystrophy (DMD) therapies that are designed to treat the underlying cause of the disease.

GENE THERAPY DEVELOPMENT

GENE THERAPY DEVELOPMENT

GENE THERAPY DEVELOPMENT

Gene Therapy

OPTIMIZED TO GET TO THE HEART OF DMD

To get to the heart of DMD, it is critical for gene therapy to be delivered to skeletal and cardiac muscle.

Our goal is to develop therapies to treat 100% of individuals with this devastating disease.

DEDICATED PATIENT SUPPORT
DEDICATED PATIENT SUPPORT
DEDICATED PATIENT SUPPORT
SareptAssist™

Our commitment to the patients and families impacted by Duchenne muscular dystrophy extends beyond treatment. We are proud to offer SareptAssist™, a patient support program for those seeking information on therapy.

Transformation, Within Reach™
Transformation, Within Reach™
Transformation, Within Reach™
Duchenne Program

Our unique RNA-based technology has the potential to advance treatments in numerous areas of high unmet need. We are continuing to advance our clinical programs for Duchenne muscular dystrophy.

JOIN US, WE'RE HIRING

JOIN US, WE'RE HIRING

JOIN US, WE'RE HIRING

Join Us

We're looking for people who exhibit teamwork, excellence, innovation, drive, compassion, and resilience. If you thrive in an environment where you can make a real difference in people's lives and where you're challenged to be the best that you can be, we encourage you to come be part of our mission.

STRATEGIC PARTNERSHIPS
STRATEGIC PARTNERSHIPS
STRATEGIC PARTNERSHIPS
Strategic Partnerships

We seek collaborations with leaders in industry, government, and academia to make meaningful advances in medicine. Our proprietary and highly versatile RNA-based technologies form the foundation of our partnering strategy.